Less Risk, More Reward: DoD Proposed Rule on Operational Contract Support Expands Overseas Contracting Opportunities
Client Alert | 1 min read | 01.22.21
On the heels of a 2019 Government Accountability Office report that recognized the Department of Defense’s (DoD) efforts in reducing risks associated with overseas operational contract support (OCS), DoD issued a proposed rule updating its OCS policies and procedures. The proposed rule continues DoD’s focus on enhancing its ability to effectively oversee, manage, and account for contractors supporting U.S. military operations to reduce the risk of fraud, waste, and abuse. This proposed rule seeks to:
- Broaden the types of overseas operations for which contracted support may be used, to include non-contingency operations, such as humanitarian assistance or peace operations, or overseas military exercises;
- Clarifies contractors’ responsibilities for deploying personnel in support of overseas operations, including medical and dental fitness standards;
- Details the services that DoD is authorized to provide contractors; and
- Promotes efficiency and transparency by removing internally-facing information requirements.
If adopted, this proposed rule will broaden the scope of military operations for which contractor support could be deployed. It would also provide clarity and consistency to other OCS procedures to allow contractors to better plan for compliance and the DoD to more effectively oversee contractors’ OCS performance. Comments on the proposed rule are due March 8, 2021.
Contacts
Insights
Client Alert | 2 min read | 09.18.25
On September 9, 2025, the U.S. Department of Health and Human Services (HHS) and the Food and Drug Administration (HHS) issued a news release announcing an “aggressive[]” “crackdown” on direct-to-consumer pharmaceutical advertising. This release came on the heels of a Presidential Memorandum President Trump issued the same day directing HHS to “ensure transparency and accuracy in direct-to-consumer prescription drug advertisements,” and the FDA to “take action to enforce legal requirements that advertisements for prescription drugs be truthful and not misleading.”
Client Alert | 3 min read | 09.17.25
Client Alert | 4 min read | 09.17.25
Client Alert | 5 min read | 09.16.25
Bucking the Odds: Why Technology Companies Should Embrace Software Patents Today